How Will The Desmoid Tumors Market Expand At A CAGR Of 6.7% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Desmoid Tumors Market?
The market size for desmoid tumors has seen robust growth in the past few years. The market is expected to leap from $2.97 billion in 2024 to $3.15 billion in 2025, advancing at a compound annual growth rate (CAGR) of 6.3%. The significant growth during the historical period is due to improvements in medical imaging, breakthroughs in genetic research and understanding, surgical innovations, heightened awareness and education, as well as patient advocacy.
In the coming years, the market size for desmoid tumors is projected to exhibit significant growth. It’s expected to reach $4.08 billion by 2029 with a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be attributed to factors such as targeted therapies, personalized medicine, enhanced global collaborations, regulatory confirmations for novel treatments, and patient-focused strategies. The forecast period will also witness major trends such as progress in treatment methodologies, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, and patient advocacy and support.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp
What Drivers Are Accelerating Expansion Of The Desmoid Tumors Market?
The increasingly prevalent occurrences of cancer are predicted to stimulate the expansion of the desmoid tumor market. Cancer is a group of related diseases characterized by abnormal cell growth and rampant spread, which can intrude into surrounding tissues and organs causing damage. This global rise in cancer incidents has ignited an increased need for sophisticated and effective chemotherapeutic agents, subsequently positively impacting the market for desmoid tumors. For instance, the National Cancer Institute, a U.S. Federal government agency, forecasted that in May 2024 there will be around 2,001,140 new instances of cancer in the U.S., with an anticipated 611,720 fatalities from the disease. In 2022, nearly 20 million new cases and 9.7 million deaths associated with cancer were reported globally. By 2040, the annual number of new cancer cases is predicted to reach 29.9 million, and the number of cancer-associated deaths to total 15.3 million. As a result, the escalating occurrences of cancer are fueling the expansion of the desmoid tumor market.
What Are The Primary Segmentation Parameters In The Desmoid Tumors Market?
The desmoid tumorsmarket covered in this report is segmented –
1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
Subsegments:
1) By Surgery: Wide Excision; Minimally Invasive Surgery
2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids
4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy
6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies
7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies
How Are Market Trends Influencing Competition In The Desmoid Tumors Market?
Top-tier companies in the desmoid tumors market are focusing on the creation of innovative drugs like nirogacestat to cater to the needs of their existing customers more effectively. Nirogacestat is an orally taken gamma-secretase inhibitor with a small molecular structure. In February 2023, for example, SpringWorks Therapeutics Inc., a clinical-stage biopharmaceutical enterprise based in the United States, received acceptance and priority review for their new drug application (NDA) for nirogacestat, intended for the treatment of adults suffering from desmoid tumors, from the U.S. Food and Drug Administration (FDA). It is believed that nirogacestat operates by hindering the synthesis of notch proteins resulting in tumor cell death. Desmoid tumors are characterized by the high production of notch protein, a factor assumed to foster their proliferation. Furthermore, nirogacestat presents an alternative form of therapy for patients which could potentially enhance treatment results.
Which Players Are Shaping The Competitive Landscape Of The Desmoid Tumors Market?
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report
What Are The Emerging Regional Trends Driving The Desmoid Tumors Market?
North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=13228&type=smp
Browse Through More Reports Similar to the Global Desmoid Tumors Market 2025, By The Business Research Company
Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025
Tumor Infiltrating Lymphocytes Global Market Report 2025
Solid Tumor Cancer Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
